Drug Profile


Alternative Names: PAC-1; Procaspase activating compound 1; VO-100

Latest Information Update: 10 Mar 2015

Price : $50

At a glance

  • Originator Vanquish Oncology
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Caspase 3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies; Solid tumours

Most Recent Events

  • 09 Feb 2015 Vanquish Oncology in collaboration with University of Illinois plans a phase I trial in Solid tumours and Haematological malignancies (Late-stage disease; second-line therapy or greater) in USA (NCT02355535)
  • 01 Feb 2015 Phase-I clinical trials in Haematological malignancies (Late-stage disease, Second-line therapy or greater) in USA (PO)
  • 01 Feb 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top